21 results about "Liquid Dosage Form" patented technology

A pharmaceutical liquid dosage form of Trientine and / or pharmaceutically acceptable salts thereof is provided, which are suitable for oral administration. A process of preparing the liquid dosage form and use for treatment of Wilson's disease and related diseases are also provided.

Described herein are dosage forms comprising the compound:wherein the dosage form can be a solid dosage form, a liquid dosage form, or a solid amorphous dispersion.

This invention discloses an oral liquid for middle-aged and elderly men to cleanse blood, protect the brain, and promote hair growth, as well as its preparation method, belonging to the field of functional health food technology. Each bottle contains 50ml net content, one bottle daily, and is free of eight major allergens. The ingredients include resistant dextrin, erythritol, DHA algal oil microcapsule powder, phosphatidylserine, natto freeze-dried powder, various medicinal and edible extracts, ginseng, vitamins, folic acid, and purified water. This invention upgrades a solid beverage into an easily absorbed oral liquid dosage form, which is rapidly absorbed, does not harm the stomach and intestines, and can cleanse blood vessels, purify blood, assist in regulating blood pressure, blood sugar, and cholesterol, prevent and intervene in Alzheimer's disease, improve memory, and promote hair growth and darkening. The production process is mature and stable, suitable for industrial production, and is specially designed for middle-aged and elderly men, making it safe for long-term consumption.

The invention discloses a system and a method for rapidly selecting a human body nutrient solution dosage form, and belongs to the technical field of biomedical detection. The system comprises a sample preprocessing unit, an integrated sensor unit and a microprocessor unit, a core theoretical model is established by taking conductivity k and refractive index n as a core quantitative basis, then core quantitative calculation and proportion estimation are performed by taking pH and turbidity as qualitative recognition and correction factors, and finally, nutrient solution supplement suggestions are intelligently decided and output. According to the method, the leap that quantitative estimation can be achieved only by rough judgment depending on experience of doctors when the nutrient solution is supplemented to a patient with the nutrient solution lost is achieved, the result is more scientific and reliable, the technical problem that component analysis of approximate chromatography is achieved through a low-cost and rapid method is solved, and the method has good clinical application value and market prospects.

Disclosed herein are novel IEX-NSAID complexes comprising a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof bound to an ion-exchange (IEX) resin, as well as liquid dosage forms thereof, and their use for treating, ameliorating, preventing, or reducing the severity of numerous conditions, or their symptoms, for with NSAID are the prescribed treatment. Also disclosed herein are methods for making the aforementioned IEX-NSAID complexes, and liquid dosage forms thereof.

The invention discloses a low-disubstituted impurity ciprofloxacin hydrochloride liquid pharmaceutical preparation and a preparation method thereof, and belongs to the field of pharmacy. Aiming at the problem that the light stability and the damp-heat stability of the existing ciprofloxacin hydrochloride solution preparation are difficult to improve synchronously, the preparation disclosed by the invention is composed of ciprofloxacin hydrochloride, tryptophan, weakly acidic buffer pair salt, a solvent and pharmaceutically acceptable auxiliary materials, and the pH value of the preparation is 5.5-7.0. According to the invention, tryptophan is added and the pH is cooperatively regulated, so that the light stability and the damp-heat stability of the preparation are remarkably improved, and the preparation process is simple, convenient and controllable, can be adapted to various liquid dosage forms such as injections, eye drops and oral solutions, and has a good industrial conversion prospect.

The utility model relates to the technical field of quality detection in the pharmaceutical industry, discloses a manual lamp inspection auxiliary tool for pre-filled syringe liquid dosage form products, and aims to improve the lamp inspection efficiency and reduce the labor cost. The tool comprises a clamping body composed of two oppositely arranged clamping plates, and clamping force is applied between the clamping plates through a torsional spring. The clamping plate is provided with a clamping part, and the clamping part is provided with a flexible material or a clamping head, so that a plurality of pre-filled syringes can be clamped at one time. And a detachable combined structure is adopted between the clamping part and the clamping plate. And the front end of the clamping part is provided with the LED lighting device with adjustable brightness, so that the detection precision is improved. The inner sides of the clamping plates are coated with anti-static coatings, and static interference is prevented. And the clamping block is provided with a buffer pad and a stepped groove to adapt to different bottleneck sizes and protect bottle bodies. And due to the arrangement of the opening part and the grasping part, the product can be conveniently clamped and turned over. The device is simple in structure and convenient to operate, the efficiency of manual lamp inspection is remarkably improved, and the device is suitable for large-scale production and quality inspection of pre-filled syringes.

The present disclosure relates to compositions comprising coenzyme Q10 and a water soluble excipient, and methods for treating coenzyme Q10 deficiency in a subject, including oral administration of the composition. The composition can be in a solid or liquid dosage form, such as a ball, a granule, a tablet, a capsule, an oral solution and a soft capsule, and is used for oral administration. The composition may comprise coenzyme Q10 and a binder mixture coated on a tablet core, wherein the tablet core comprises a sugar, microcrystalline cellulose, or a mixture thereof. The composition is an immediate release formulation having high solubility in an aqueous medium.

The application discloses a method for evaluating the stability of a liquid dosage form medicine packaged in a vial and application thereof. Compared with a traditional filling process, the application controls the mass-volume ratio of oxygen in the injection liquid, reduces the difference in the residual oxygen amount in the headspace between batches of products, is highly repeatable and controllable. The application provides a reliable basis for parameter setting in the production and processing process of oxygen-sensitive injection liquid, helps to promote the product quality improvement of the injection liquid medicine, reduces quality problems caused by oxygen, maintains the long-term stability of the injection liquid medicine in the storage and transportation process, and saves production cost.

Disclosed herein are novel IEX-NSAID complexes comprising a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof bound to an ion-exchange (IEX) resin, as well as liquid dosage forms thereof, and their use for treating, ameliorating, preventing, or reducing the severity of numerous conditions, or their symptoms, for with NSAID are the prescribed treatment. Also disclosed herein are methods for making the aforementioned IEX-NSAID complexes, and liquid dosage forms thereof.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The present invention relates to a controlled-release multilayer microparticle containing a pharmaceutically active compound, said microparticle being intended for oral administration or direct administration to the stomach in the form of a liquid pharmaceutical composition. It also relates to the liquid pharmaceutical composition containing it, a kit for preparing said liquid pharmaceutical composition, a pharmaceutical solid composition intended for reconstitution in the form of said liquid composition and a process for preparing said liquid composition.

According to a first aspect of the invention, there is provided health supplement composition comprising: a therapeutically effective amount of at least one active ingredient selected from Calcium Carbonate, Maize Starch, Magnesium Stearate, Microcrystalline Cellulose, Vitamin D3, and Vitamin K2; and at least one pharmaceutically acceptable excipient selected from the group consisting of binders, disintegrants, stabilizers, lubricants, diluents, and preservatives, wherein the composition is formulated for oral administration in a powder, tablet, capsule, or liquid dosage form.In an embodiment, the composition is provided in a powder / granular form, typically packaged in tablets, as well as in a liquid form or as an additive to a liquid such as water, juice, or vegetable glycerine. Other delivery forms for the novel supplement may be utilized to meet particular operating circumstances or environments. Consequently, the invention is not limited to a specific delivery system but covers any and all suitable delivery systems.

A payload delivery module (120) for an ingestionable device comprises a piston (121), a hollow needle (122), a membrane (129), a fluid dosage form (130), and a valve (125). The piston (121) has an interior (121c). The needle (122) is coupled to the piston (121). The membrane (129) is coupled to the piston (121) to define a reservoir in the interior (121c). The fluid dosage form (130) is disposed within the reservoir and contains at least one therapeutic agent. The valve (125) is coupled to the piston (121) to control the flow of the fluid dosage form from the reservoir to the needle (122).

The present invention relates to a liquid dosage form pharmaceutical composition containing plasmid DNA. The liquid dosage form containing plasmid DNA according to the present invention exhibits excellent efficacy in terms of storage stability of the plasmid DNA, which is a pharma- ceutical active ingredient, and can be usefully used as a pharmaceutical composition with excellent product stability and safety.

An oral liquid composition according to the present invention comprises tegoprazan or a pharmaceutically acceptable salt thereof as an active ingredient, a solubilizing agent, and an extra solvent. The present invention has improved the problem of residual foreign body sensation of orally disintegrating tablets conventionally developed for patients with dysphagia. In addition, it is possible to provide a new treatment option for an increasing patient group with gastric acid-related diseases by securing excellent stability of the active ingredient in a solution state, which is a characteristic of an oral liquid dosage form, and presenting a dosage form that ensures uniformity of a preparation.

The present invention concerns controlled-release multilayer microparticle containing a pharmaceutically active compound, said microparticle being intended for oral administration or direct administration in the stomach in the form of a liquid pharmaceutical composition. It concerns also the liquid pharmaceutical composition containing it, a kit for the preparation of said liquid pharmaceutical composition, a pharmaceutical solid composition intended to be reconstituted in the form of said liquid composition and a process of preparation of said liquid composition.

The application discloses a preparation method of glycine ferrous without obvious iron smell in a liquid agent product, and relates to the technical field of food or health product processing. The method comprises the following steps: preparing a first solution by hot water swelling of gamma-cyclodextrin; preparing a second solution by adding glycine ferrous and vitamin C or citric acid into the first solution after cooling; preparing a third solution by dissolving soluble soybean polysaccharide or pectin in water and then adding malt dextrin; and then slowly adding the second solution into the third solution, and then performing high-pressure homogenization and spray drying. Through the synergistic effect of gamma-cyclodextrin inclusion, acidic auxiliary protection and double embedding of a film forming agent, the prepared glycine ferrous is clear and free of precipitation in hot water, has no obvious iron smell, and has a significantly improved absorption rate, and is particularly suitable for liquid dosage forms such as oral liquids.

The invention belongs to the technical field of microorganisms, and particularly relates to loess rhizobium and a duplex bag rhizobium inoculant adopting the loess rhizobium. The rhizobium can provide nitrogen nutrition guarantee for good growth of Astragalus mongholicus plants as a Zhongmongolian medicinal material, solves the important problem of long-term lack of nitrogen nutrition in soil, and is extremely urgent to screen and develop the rhizobium with high nitrogen fixation efficiency and high competitive nodulation efficiency. The loess rhizobium duplex bag rhizobium inoculant provided by the invention has a growth promoting effect on plants and can be inoculated at any time in the whole growth period of the plants. The preparation method and the application method are simple and easy to implement, the problem that liquid dosage forms are prepared from radix astragali rhizobium is solved, rhizobium can be inoculated at any time, the nodulation rate and the nitrogen fixation rate are increased, and therefore the yield and the quality of radix astragali are improved; the rhizobium inoculant is prepared by adopting a duplex bag method, so that the problem of low nodulation rate of the rhizobium inoculant under the condition of nutrition deficiency is solved, and on the other hand, the problem that perennial astragalus mongholicus is inoculated with the inoculant for multiple times is solved.

Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and / or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

The invention discloses a nicotine oral spray mild in taste and free of pungency and a preparation method of the nicotine oral spray, and relates to the field of nicotine oral sprays.The nicotine oral spray is in a liquid dosage form and comprises a nicotine salt compound, a pH buffer system, a mucous membrane adhesive and a flavoring agent, wherein the nicotine salt compound is prepared from nicotine bitartrate, malic acid nicotine salt and nicotine citrate; according to the nicotine oral spray mild in taste and free of pungency and the preparation method of the nicotine oral spray, the nicotine bitartrate, the malic acid nicotine salt and the nicotine citrate are compounded in combination with the citric acid-sodium citrate buffer pair, so that the pungency and mucous membrane irritation of the product are reduced; mucous membrane adhesive carbomer 934P, hydroxy propyl cellulose and chitosan are compounded, so that the residence time of the medicine in oral mucosa is prolonged; and the taste of the product is improved by compounding the flavoring agent stevioside, mogroside, erythritol, L-menthol and WS-3.